BRCA2 mutations associated with improved survival for ovarian cancer
Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation.
Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation.
Kelly Metcalfe, a professor at the Bloomberg Faculty of Nursing, focuses her research on a unique population of women faced with some really tough decisions and helps them reach satisfactory conclusions.
Scientists at the University of North Carolina at Chapel Hill were among co-authors of a study that described the first isolation and purification of the BRCA2 protein which is produced by a gene whose loss ...
A key step in understanding the origins of familial breast cancer has been made by two teams of scientists at the University of California, Davis. The researchers have purified, for the first time, the protein produced by ...
Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown ...
The new drug olaparib has antitumour activity in carriers of the BRCA1 or BRCA2 gene mutations who have advanced ovarian or breast cancer, according to the findings of two proof-of-concept trials. Together with previous findings, ...
Results of a large-scale clinical trial presented today at the annual meeting of the Radiological Society of North America (RSNA) provide the first strong evidence of the benefit of annual screening ultrasound for women with ...
A recent study published in the Journal of Cancer Epidemiology has reinforced the correlation between being overweight, smoking and breast cancer. What makes this study unique is how test subjects were not diagnosed for BR ...
Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these ...